News
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...
Investor's Business Daily on MSN19h
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives
Arrowhead Pharmaceuticals stock tumbled Thursday after Sarepta Therapeutics liquefied its entire stake in the smaller biotech ...
Asianet Newsable on MSN23h
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright has a ‘Sell’ rating on the stock and a $5 price target, representing a near 75% downside from the stock’s ...
AbbVie unveiled a $195 million investment to expand active pharmaceutical ingredient manufacturing in the U.S. Bloomberg reported that BlinkRx, a company that has Donald Trump Jr. on its board, just ...
Sarepta stock has been in free fall since safety issues derailed Elevidys, a gene therapy analysts had expected to achieve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback